Announced details
Treatment of malignant brain tumors (glioblastoma, GBM). Monotherapy and combination therapy with standard treatment.
Accumulation in intracranial tumors was confirmed in a PDX model, and survival was significantly extended with monotherapy and combination therapy with standard treatment (specific figures are Not disclosed).
The parties are conducting joint research in the oncology field.
University of California, San Francisco (UCSF), United States. Other information, including location, representative, and business activities, is Not disclosed.
Kyoto International Conference Center (Kyoto, Kyoto Prefecture)
There will be no impact on consolidated results for the fiscal year ending December 2026.
The company does not address Contract Value / Offering price.
85th Annual Meeting of the Japanese Cancer Association
| Item | Details |
|---|---|
| Names of Products / Services Covered | Brincidofovir (brincidofovir, IV BCV) |
| Counterparty | University of California, San Francisco (UCSF), United States |
| Counterparty overview | University of California, San Francisco (UCSF), United States. Other information, including location, representative, and business activities, is Not disclosed. |
| Relationship with the Company | The parties are conducting joint research in the oncology field. |
| Launch date | 24 September 2026 (scheduled; conference poster presentation) |
| Applicable area | Treatment of malignant brain tumors (glioblastoma, GBM). Monotherapy and combination therapy with standard treatment. |
| Location | Kyoto International Conference Center (Kyoto, Kyoto Prefecture) |
| Quantitative Effects | Accumulation in intracranial tumors was confirmed in a PDX model, and survival was significantly extended with monotherapy and combination therapy with standard treatment (specific figures are Not disclosed). |
| Impact on Business Performance | There will be no impact on consolidated results for the fiscal year ending December 2026. |
| Source | 85th Annual Meeting of the Japanese Cancer Association |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because IV BCV accumulation in intracranial tumors and a significant extension of survival were confirmed in a PDX (patient-derived cancer cell) intracranial transplantation model.